Zydus Lifesciences Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Zydus Lifesciences Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: Deven Choksey

Keep track of all breaking news and updates on Zydus Lifesciences Ltd. from all sources in a single place.

Zydus Lifesciences Ltd.

02 Sep 2025, 12:01PM

996.10

0.51%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

pdf

Zydus Lifesciences Ltd.

29 Aug 2025

996.10

0.51%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis.

pdf

Zydus Lifesciences Ltd.

26 Aug 2025

996.10

0.51%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Change in senior management

pdf

Zydus Lifesciences Ltd.

26 Aug 2025

996.10

0.51%

Company Update

Zydus Lifesciences Ltd - 532321 - Intimation Of ESG Rating

BSE India

Intimation of ESG Rating

pdf

Zydus Lifesciences Ltd.

25 Aug 2025

996.10

0.51%

Q1FY26 performance stood stable amid slower traction in US offset by new product launches

Buy: Zydus Lifesciences Ltd.

Target

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +2.6%/-7.4% as we bake in slower revenue growth as Revlimid and Mirabegron sales is expected to taper-off and factor in a marginal increase in EBITDA margins in FY26, while we factor in weaker margins on the back of changing product mix towards competitive generics over FY27.

Zydus Lifesciences L.. has an average target of 1021.00 from 6 brokers.

Zydus Lifesciences Ltd.

20 Aug 2025

996.10

0.51%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication of notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati Editions, both on August 20, 2025.

pdf

Zydus Lifesciences Ltd.

20 Aug 2025

996.10

0.51%

Earnings Call

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of the post results earnings call held on August 12, 2025

pdf

Zydus Lifesciences Ltd.

13 Aug 2025

996.10

0.51%

Company Update

Zydus Lifesciences Ltd - 532321 - Update

BSE India

Closure of USFDA inspection at Zydus'' formulation manufacturing plant at Baddi

pdf

Zydus Lifesciences Ltd.

13 Aug 2025

996.10

0.51%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Closure of USFDA inspection at Zydus'' formulation manufacturing plant at SEZ II, Ahmedabad.

pdf

Zydus Lifesciences Ltd.

13 Aug 2025

996.10

0.51%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

The newspaper cutting with regard to publication of unaudited financial results for the quarter ended on June 30, 2025, in Financial Express on August 13, 2025.

pdf

Is Cadila Healthcare Ltd. worth buying?

856 Votes:

Buy 81.78%

Sell 9.93%

Hold 8.29%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf